JenaValve Technology: The company received $100 million of development capital from Bain Capital Life Sciences, Peijia Medical, Gimv, Andera Partners, RMM Ventures, Valiance, VI Partners, Cormorant Asset Management, Pictet, Qatar Investment Authority and Innovatus Capital Partners on August 31, 2022. The company is a developer of transcatheter heart valve replacement systems designed to treat severe, symptomatic aortic regurgitation and stenosis.
Photys: The company raised $75 million of Series A venture funding in a deal led by MPM Capital on September 8, 2022. The company is a developer of bifunctional drugs designed for phosphorylation of kinases, and potentially phosphatases.
Upfront: The company raised $72.0 million of Series C venture funding in a deal led by Baird Capital, First Trust Capital Partners and Echo Health Ventures on September 6, 2022. The company is a developer of a patient navigation platform designed to book virtual or in-person care.
Inspirna: The company raised $55 million of Series D venture funding in a deal led by Sands Capital and Vivo Capital on August 29, 2022, putting the company’s pre-money valuation at $65 million. The company is a developer of novel cancer drugs designed to target key pathways in cancer progression.
MedGenome: The company received $50 million of development capital from Novo Holdings, Sofina and Leapfrog Investments on August 30, 2022. The company is a developer of sequencing genomics-based diagnostics and research platform intended to improve global health.
Vilya: The company raised $50 million in funding in a deal led by ARCH Venture Partners on August 29, 2022, putting the company’s pre-money valuation at $63 million. The company is a developer of a biotechnology platform designed for creating a novel class of medicines to precisely target disease biology.
Elephas: The company raised $41.5 million of Series B venture funding in a deal led by ARCH Venture Partners on September 6, 2022, putting the company’s pre-money valuation at $104 million. The company is an operator of a live tumor imaging diagnostics company intended to help determine the cancer therapy for each patient.
Antheia: The company raised $40 million of venture funding from undisclosed investors on August 31, 2022. The company is an operator of a biotechnology business intended to develop plant-inspired medicines.
Medivis: The company raised $22.0 million of venture funding from undisclosed investors on September 6, 2022. The company is a developer of a medical imaging technology designed to utilize augmented reality for surgical operations.
98point6: The company raised $20 million of venture funding in form of convertible notes from L Catterton and Activant Capital on September 1, 2022. The company is a developer of an on-demand text-based primary care platform designed to make healthcare accessible and affordable to everyone.
Pleco Therapeutics: The company raised EUR 17.3 million of Series A venture funding from Hyloris Pharmaceuticals, Oost NL, and Netherlands Enterprise Agency on September 6, 2022. The company is a developer of therapies intended to treat cancer and improve the effectiveness of existing chemotherapy.
InsideTracker: The company raised $15 million of Series B venture funding in a deal led by PeakBridge Partners on September 8, 2022. The company is a developer of a health analytics platform intended to analyze blood, DNA, and lifestyle habits and guide users to their health goals with actionable recommendations.
VastBiome: The company raised $14.5 million of venture funding from 3CC | Third Culture Capital on September 7, 2022. The company is an operator of a biotechnology agency intended to transform cancer therapy through the microbiome.
Venatorx Pharmaceuticals: The company raised $12.7 million of Series C1 venture funding from undisclosed investors on September 2, 2022, putting the company’s pre-money valuation at $70 million. The company is a developer of antibacterial and antiviral drugs designed to treat multi-drug-resistant (MDR) bacterial infections.
RapidPulse: The company raised $10.6 million of venture funding from undisclosed investors on August 31, 2022. The company is a developer of medical devices designed to treat ischemic stroke.
Xellar Biosystems: The company raised $10 million of venture funding in a deal led by Legend Capital on August 30, 2022. Yael Capital and ZhenFund also participated in the round. The company is a developer of a biotechnology research tool designed to accelerate drug discovery and development.
AiVita Biomedical: The company raised $6.0 million of venture funding from undisclosed investors on August 30, 2022. The company is a developer of immunotherapy intended to treat cancer and vision loss.
AngelMed: The company raised $6 million of venture funding in the form of convertible debt from undisclosed investors on September 6, 2022. The company is a developer of a cardiac monitoring and alerting device designed to improve cardiovascular care.
M13 Therapeutics: The company raised $5 million of venture funding from Ovid Therapeutics on September 6, 2022. The company is a developer of a bacteriophage-based platform designed to treat human disease and create impactful science in the field of genomic medicines.
CereScan: The company raised $4.5 million of venture funding in the form of convertible debt from undisclosed investors on September 7, 2022. The company is a provider of brain-imaging services intended to diagnose brain injuries or brain disorders.
Healios: The company raised an undisclosed amount of venture funding from Zühlke Ventures, Lichtsteiner Foundation and other undisclosedl investors on August 31, 2022. The company is a developer of digital biomarkers that accompany and accelerate new drug development in neuroscience.
